A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events

Author： Addison Christina   Bouganim Nathaniel   Hilton John   Vandermeer Lisa   Dent Susan   Amir Eitan   Hopkins Sean   Kuchuk Iryna   Segal Roanne   Song Xinni   Gertler Stan   Mazzarello Sasha   Dranitsaris George   Ooi Daylily   Pond Gregory   Clemons Mark  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.144, Iss.3, 2014-04, pp. : 615-624

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer

By Modi Shanu  

Breast Cancer Research and Treatment, Vol. 90, Iss. 2, 2005-03 ,pp. : 157-163

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy

By Morrow Phuong   Divers Stephen   Provencher Louise   Luoh Shiuh-Wen   Petrella Teresa   Giurescu Marius   Schmelter Thomas   Wang Yao   Hortobagyi Gabriel   Vahdat Linda  

Breast Cancer Research and Treatment, Vol. 123, Iss. 3, 2010-10 ,pp. : 837-842

Springer Publishing Company

Access to resources Recommend Favorite

Disease Progression Increases the Risk of Skeletal-Related Events in Patients With Bone Metastases From Castration-Resistant Prostate Cancer, Lung Cancer, or Other Solid Tumors

By Simon Tchekmedyian N.   Chen Yin-Miao   Saad Fred  

Cancer Investigation, Vol. 28, Iss. 8, 2010-09 ,pp. : 849-855

Informa Healthcare

Access to resources Recommend Favorite

Bisphosphonate Therapy for Patients with Breast Cancer

By  

Current Cancer Therapy Reviews, Vol. 1, Iss. 3, 2005-01 ,pp. : 217-225

Bentham Science Publishers

Access to resources Recommend Favorite

Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer

By Wildiers H.  

Breast Cancer Research and Treatment, Vol. 123, Iss. 2, 2010-09 ,pp. : 463-469

Springer Publishing Company

Access to resources Recommend Favorite